MedTrace Logo

The Efficacy of Fycompa (Perampanel) in Children With Epilepsy

NCT04608799 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2020-10-29

No results posted yet for this study

Summary

Fycompa (Perampanel), a new anti-epileptic drug that uses a new mechanism-AMPA receptor antagonist. Its initial indication is for local or generalized epilepsy in children and adults over 12 years old, but its effectiveness in the treatment of epilepsy in children At present, more evidence is still needed. We will study the effectiveness of Fycompa (Perampanel) in the treatment of epilepsy in children under the age of 18. It is expected that the clinical use of Fycompa (Parampanel) in Taiwan will be able to analyze and study the effectiveness of the clinical use of Fycompa (Parampanel) in the treatment of epilepsy in children, and compare it with foreign reports.

Conditions

  • Neurologic Disorder

Interventions

DRUG

Perampanel

Efficacy of epilepsy drugs

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • WangTso Lee, MD · National Taiwan University Hospital

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-03-19
Completion
2020-03-19

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04608799 on ClinicalTrials.gov